Sensyne Health, the clinical AI Company has received the UK regulatory approval for its SYNE-COV machine learning algorithm that accurately predicts the risk of COVID-19.
SYNE-COV performed an analysis on more than 60 variables in the patient’s electronic health record to predict the possibility that a patient that tested positive to COVID-19 will develop a serious illness that requires ventilation or ICU admission. This analysis offers the risk prediction as well as an explanation of the result to help doctors treat patients who have been hospitalized with COVID-19 infection.
The collaboration between Sensyne and the NHS Foundation Trust of Chelsea & Westminster Hospitals gave birth to the development of the SYNE-COV product. It becomes the first algorithm developed from SENSE clinical and operational algorithm engine to receive regulatory approval in the UK. SENSE uses the analysis of data in electronic patient records to generate clinical AI algorithms (called SYNE)to help clinicians make decisions. The company currently has several algorithms in development for various medical conditions that, pending regulatory approval, intend to commercialize to UK healthcare providers and those overseas.
With regulatory approval, Sensyne can now market SYNE-COV across the UK. Also, the algorithm will now be marketed to the NHS Trusts by the company to help them prepare for COVID-19 and deploy the algorithm at the perfect moment for the 2021/22 winter season.
“We are excited about the opportunity this opens up. This is personalized care that uses patients’ own data to layer risks and predict responses to clinical treatments in order to inform and support clinical decisions. This is a real milestone in advancing digital innovation, data integration and analytics to improve patient care in the NHS.” commented the Hospital Director of the NHS Foundation Trust of Chelsea and Westminster Hospital, Dominic Conlin.
Lord (Paul) Drayson, the CEO of Sensyne Health, added, “This is the first-ever Sensyne clinical AI algorithm developed using our clinical AI platform that has the privilege of getting regulatory approval. Under a range of medical conditions, the SENSE engine has the expectation of generating clinical algorithm which offers real-time support for clinical decision-making. Obtaining the first regulatory approval is an important milestone for the company and we are looking forward to helping the NHS roll out the SYNE-COV.”